4.8 Article

The genetic basis and cell of origin of mixed phenotype acute leukaemia

Journal

NATURE
Volume 562, Issue 7727, Pages 373-+

Publisher

NATURE RESEARCH
DOI: 10.1038/s41586-018-0436-0

Keywords

-

Funding

  1. American Lebanese Syrian Associated Charities of SJCRH
  2. Cookies for Kids Cancer
  3. St. Baldrick's Foundation Robert J. Arceci Innovation Award
  4. Henry Schueler 419 Foundation
  5. SJCRH Physician Scientist Training Program Fellowship
  6. National Cancer Institute [P30 CA021765, U10 CA98413, U24 CA114766, R35 CA197695]
  7. Federal funds from National Cancer Institute, National Institutes of Health [HHSN261200800001E]
  8. NATIONAL CANCER INSTITUTE [U10CA180886, R35CA197695, U10CA098413, U24CA114766, P30CA021765, U10CA180899, R01CA114563] Funding Source: NIH RePORTER
  9. NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM115279] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Mixed phenotype acute leukaemia (MPAL) is a high-risk subtype of leukaemia with myeloid and lymphoid features, limited genetic characterization, and a lack of consensus regarding appropriate therapy. Here we show that the two principal subtypes of MPAL, T/myeloid (T/M) and B/myeloid (B/M), are genetically distinct. Rearrangement of ZNF384 is common in B/M MPAL, and biallelic WT1 alterations are common in T/M MPAL, which shares genomic features with early T-cell precursor acute lymphoblastic leukaemia. We show that the intratumoral immunophenotypic heterogeneity characteristic of MPAL is independent of somatic genetic variation, that founding lesions arise in primitive haematopoietic progenitors, and that individual phenotypic subpopulations can reconstitute the immunophenotypic diversity in vivo. These findings indicate that the cell of origin and founding lesions, rather than an accumulation of distinct genomic alterations, prime tumour cells for lineage promiscuity. Moreover, these findings position MPAL in the spectrum of immature leukaemias and provide a genetically informed framework for future clinical trials of potential treatments for MPAL.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available